Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthequity (HQY) Research & Development (2016 - 2026)

Healthequity has reported Research & Development over the past 14 years, most recently at $70.4 million for Q1 2026.

  • Quarterly results put Research & Development at $70.4 million for Q1 2026, up 8.82% from a year ago — trailing twelve months through Jan 2026 was $262.5 million (up 9.6% YoY), and the annual figure for FY2026 was $262.5 million, up 9.6%.
  • Research & Development for Q1 2026 was $70.4 million at Healthequity, up from $65.9 million in the prior quarter.
  • Over the last five years, Research & Development for HQY hit a ceiling of $70.4 million in Q1 2026 and a floor of $45.2 million in Q2 2022.
  • Median Research & Development over the past 5 years was $55.6 million (2023), compared with a mean of $56.5 million.
  • Biggest five-year swings in Research & Development: soared 42.11% in 2022 and later increased 4.77% in 2024.
  • Healthequity's Research & Development stood at $48.9 million in 2022, then rose by 13.75% to $55.6 million in 2023, then increased by 8.23% to $60.2 million in 2024, then rose by 9.52% to $65.9 million in 2025, then increased by 6.73% to $70.4 million in 2026.
  • The last three reported values for Research & Development were $70.4 million (Q1 2026), $65.9 million (Q4 2025), and $64.8 million (Q3 2025) per Business Quant data.